Drugs / Ginkgo biloba dropping pills
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04529148 | Sep 2020 → Sep 2022 | intermediate coronary syndrome | Wanbangde Pharmaceutical Group Co., LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgo biloba dropping pills | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04529148 ↗ |
| Known as | GBDPs | “Ginkgo biloba extract (GBE), the raw material of Ginkgo biloba dropping pills (GBDPs), is widely used to treat various conditions, including cardiovascular disease, ischaemic...” PMID 37164472 ↗ May 2023 |
| Route | Oral | “Ginkgo biloba dropping pills (63mg / pill) , oral, 5 pills each time, three times a day” NCT04529148 ↗ |